
BlossomHill Therapeutics (NASDAQ: BLSM) has announced a collaboration with Foundation Medicine, a wholly owned subsidiary of Roche (SIX: RO, ROP; OTCQX: RHHBY), to develop the first companion diagnostic assay (CDx) for BH-30643 in EGFR C797S-mutated non-small cell lung cancer (NSCLC).
The collaboration will leverage the ongoing Phase 1/2 SOLARA clinical trial evaluating BH-30643 in the targeted treatment of epidermal growth factor receptor (EGFR)-mutant NSCLC patients to validate the assay. EGFR C797S is the most common EGFR mutation driving resistance to osimertinib treatment in EGFR-mutant NSCLC. BH-30643 is a macrocyclic mutant-selective OMNI-EGFR inhibitor that has demonstrated clinical activity against a variety of EGFR mutations, in particular the C797S mutation that drives resistance to standard therapy.
In a statement, Geoff Oxnard, MD, chief medical officer at BlossomHill, commented, “Our near-term development priority for BH-30643 is to address the unmet needs of EGFR-mutant NSCLC patients with known resistance mutations following progression on prior EGFR targeted therapy. Foundation Medicine is the most experienced developer of precision CDx assays and the ideal partner to help us characterize EGFR resistance and validate a CDx assay to support the development of our medicine.”






